WS #13127
Holding: newest synthesis is 104d 8h old
Novo Nordisk plunged ~$21B in market cap after its heart drug Ziltivekimab failed a Phase 3 trial, a high-significance single-name event.
Novo Nordisk drug trial failure
Novo Nordisk plunged ~$21B in market cap after its heart drug Ziltivekimab failed a Phase 3 trial, a high-significance single-name event.